导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.21% | 1918/4773 |
| 近一周 | -3.09% | 3651/5462 |
| 近一月 | -9.68% | 4818/5421 |
| 近一季 | -18.28% | 4676/5209 |
| 近半年 | -1.66% | 1659/4920 |
| 近一年 | 5.67% | 1564/4366 |
| 近两年 | 110.71% | 471/2954 |
| 近三年 | 66.79% | 353/2253 |
| 成立以来 | 88.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.99% 2053/4961 |
33.80% 973/5312 |
- - |
- - |
| 2025 | 48.36% 531/4813 |
-1.33% 2639/3635 |
3.20% 1112/4076 |
46.87% 506/4524 |
-0.80% 2645/4813 |
| 2024 | 16.92% 746/3463 |
-3.59% 1527/2808 |
-5.98% 1826/3014 |
27.61% 215/3129 |
1.08% 1125/3463 |
| 2023 | -17.70% 1755/2656 |
2.16% 1423/2280 |
-6.79% 1710/2385 |
-8.96% 1754/2515 |
-5.06% 1245/2655 |
| 2022 | -27.66% 1498/2207 |
-18.85% 1405/1919 |
5.63% 855/2016 |
-17.42% 1590/2113 |
2.20% 1011/2208 |
| 2021 | 10.94% 410/1822 |
-6.47% 1006/1255 |
24.25% 110/1330 |
-6.42% 927/1466 |
2.02% 725/1822 |
| 2020 | 60.54% 122/1250 |
3.96% 99/1028 |
28.43% 105/1067 |
5.29% 924/1164 |
14.20% 292/1184 |
| 2019 | 40.97% 241/1092 |
32.69% 167/739 |
-9.84% 696/788 |
7.18% 99/850 |
9.94% 176/918 |
| 2018 | - - |
- - |
-11.52% 366/631 |
-10.87% 550/660 |
-10.70% 216/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 工银创业板ETF联接A VS. 长安沪深300非周期A(740101) |